← Back to Home

First-in-human trial of oral complement receptor inhibitor izicopan published, showing sustained inhibition

A Phase 1 study in 86 healthy adults provides short-term safety data and a basis for dosing izicopan. Immune responses were inhibited in blood tests, but whether this translates into therapeutic benefits for patients remains to be clinically validated.

By SURL BioNews

For an oral anti-inflammatory drug to keep working, researchers first need to confirm whether its effects can last long enough after it enters the body. InflaRx announced on November 6 that the first-in-human trial of the complement receptor inhibitor izicopan had been published in *Clinical Pharmacology in Drug Development*. The study observed sustained inhibition of the target pathway in healthy adults, with no serious adverse events reported. The paper adds study details to previously announced results; it does not provide new evidence of efficacy in patients.

Izicopan, formerly known as INF904, is an oral small-molecule drug targeting the C5a receptor C5aR1. It is designed to block C5a-driven immune cell activation. In addition to measuring drug concentrations in the blood, the study therefore tested whether participants’ blood showed a reduced response to C5a stimulation after dosing, to determine whether the drug was having its intended effect.

The randomized, placebo-controlled Phase 1 trial enrolled 86 healthy adults, of whom 66 received izicopan and 20 received placebo. All were included in the safety analysis. Single doses ranged from 3 to 240 mg. Repeat dosing tested 30 mg once daily, as well as 30 or 90 mg per dose twice daily, for 14 consecutive days.

According to the paper’s abstract, almost all dose groups achieved more than 90% inhibition of C5a-induced CD11b upregulation from days 2 to 15. CD11b is a marker used in the study to track immune cell activation. This figure describes responses in ex vivo blood tests; it cannot be interpreted as a 90% reduction in inflammation in patients or used to estimate the extent of disease improvement.

The pharmacokinetic data also provide clues for subsequent dosing schedules. With twice-daily dosing, the drug showed approximately twofold accumulation, from which the study estimated an effective half-life of about 12 hours. This helps assess how to maintain drug exposure and pathway inhibition, but appropriate doses for patients still need to be determined in conjunction with disease status and longer-term safety data.

Regarding safety, all adverse events reported in the study were mild or moderate. The company’s announcement added that the trial found no clinically meaningful changes in laboratory tests, vital signs, or electrocardiograms, among other assessments. The content distributed through GlobeNewswire was the same company announcement, rather than another independent study. Because repeat dosing lasted only 14 days and the participants were healthy adults, these results are not yet sufficient to rule out rare risks or risks associated with long-term use.

InflaRx said it would advance the development of izicopan for ANCA-associated vasculitis and other kidney diseases. The announcement also mentioned a planned exploratory study in IgA nephropathy. This paper provides a more complete pharmacological basis for subsequent trials. The key question that now needs to be answered is whether this sustained pathway inhibition can deliver measurable, sustained clinical improvements in patients.

References

  1. InflaRx
  2. PubMed / Clinical Pharmacology in Drug Development
  3. InflaRx N.V. via GlobeNewswire